Literature DB >> 28480994

Association of Human Development Index with global bladder, kidney, prostate and testis cancer incidence and mortality.

Alyssa K Greiman1, James S Rosoff2, Sandip M Prasad1,3.   

Abstract

OBJECTIVES: To describe contemporary worldwide age-standardized incidence and mortality rates for bladder, kidney, prostate and testis cancer and their association with development.
MATERIALS AND METHODS: We obtained gender-specific, age-standardized incidence and mortality rates for 184 countries and 16 major world regions from the GLOBOCAN 2012 database. We compared the mortality-to-incidence ratios (MIRs) at national and regional levels in males and females, and assessed the association with socio-economic development using the 2014 United Nations Human Development Index (HDI).
RESULTS: Age-standardized incidence rates were 2.9 (bladder) to 7.4 (testis) times higher for genitourinary malignancies in more developed countries compared with less developed countries. Age-standardized mortality rates were 1.5-2.2 times higher in more vs less developed countries for prostate, bladder and kidney cancer, with no variation in mortality rates observed in testis cancer. There was a strong inverse relationship between HDI and MIR in testis (regression coefficient 1.65, R2 = 0.78), prostate (regression coefficient -1.56, R2 = 0.85), kidney (regression coefficient -1.34, R2 = 0.74), and bladder cancer (regression coefficient -1.01, R2 = 0.80).
CONCLUSION: While incidence and mortality rates for genitourinary cancers vary widely throughout the world, the MIR is highest in less developed countries for all four major genitourinary malignancies. Further research is needed to understand whether differences in comorbidities, exposures, time to diagnosis, access to healthcare, diagnostic techniques or treatment options explain the observed inequalities in genitourinary cancer outcomes.
© 2017 The Authors BJU International © 2017 BJU International Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  bladder cancer; epidemiology; kidney cancer; prostate cancer; testis cancer

Mesh:

Year:  2017        PMID: 28480994     DOI: 10.1111/bju.13875

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  18 in total

Review 1.  Alternative therapies in patients with non-muscle invasive bladder cancer.

Authors:  Öner Şanlı; Yair Lotan
Journal:  Turk J Urol       Date:  2017-12-01

2.  Mental Health in Urologic Oncology.

Authors:  Danyon Anderson; Abrahim N Razzak; Matthew McDonald; David Cao; Jamal Hasoon; Omar Viswanath; Alan D Kaye; Ivan Urits
Journal:  Health Psychol Res       Date:  2022-08-20

3.  Intratumoral Switch of Molecular Phenotype and Overall Survival in Muscle Invasive Bladder Cancer.

Authors:  Camilla De Carlo; Marina Valeri; Noemi Rudini; Paolo Andrea Zucali; Miriam Cieri; Grazia Maria Elefante; Federica D'antonio; Rodolfo Hurle; Laura Giordano; Alessandra Bressan; Massimo Lazzeri; Matteo Perrino; Giorgio Guazzoni; Luigi Maria Terracciano; Piergiuseppe Colombo
Journal:  Cancers (Basel)       Date:  2022-07-02       Impact factor: 6.575

4.  Interactions between life expectancy and the incidence and mortality rates of cancer in China: a population-based cluster analysis.

Authors:  Xiuying Gu; Rongshou Zheng; Changfa Xia; Hongmei Zeng; Siwei Zhang; Xiaonong Zou; Zhixun Yang; He Li; Wanqing Chen
Journal:  Cancer Commun (Lond)       Date:  2018-07-03

Review 5.  Targeting the Immune system and Epigenetic Landscape of Urological Tumors.

Authors:  João Lobo; Carmen Jerónimo; Rui Henrique
Journal:  Int J Mol Sci       Date:  2020-01-28       Impact factor: 5.923

6.  Trends in incidence, mortality and survival of testicular cancer patients in Belarus.

Authors:  Alexander Rolevich; Alesia Yaumenenka; Denis Borodin; Sviataslau Semenov; Liudmila Artsiushkevich; Sergey Polyakov; Natalia Konoplia; Sergei Krasny
Journal:  Cent European J Urol       Date:  2019-12-30

Review 7.  Previous, Current, and Future Pharmacotherapy and Diagnosis of Prostate Cancer-A Comprehensive Review.

Authors:  Bartosz Malinowski; Michał Wiciński; Nikola Musiała; Ilona Osowska; Mateusz Szostak
Journal:  Diagnostics (Basel)       Date:  2019-10-25

8.  The association between incidence and mortality of brain cancer and human development index (HDI): an ecological study.

Authors:  Zaher Khazaei; Elham Goodarzi; Vahidreza Borhaninejad; Farhad Iranmanesh; Hosein Mirshekarpour; Batool Mirzaei; Hasan Naemi; Sayeed Maryam Bechashk; Isan Darvishi; Roghayeh Ershad Sarabi; Ahmad Naghibzadeh-Tahami
Journal:  BMC Public Health       Date:  2020-11-12       Impact factor: 3.295

9.  Comprehensive signature analysis of drug metabolism differences in the White, Black and Asian prostate cancer patients.

Authors:  Yang Liu; Jia-Wei Zhou; Cun-Dong Liu; Jian-Kun Yang; De-Ying Liao; Zhi-Jian Liang; Xiao Xie; Qi-Zhao Zhou; Kang-Yi Xue; Wen-Bing Guo; Ming Xia; Jun-Hao Zhou; Ji-Ming Bao; Cheng Yang; Hai-Feng Duan; Hong-Yi Wang; Zhi-Peng Huang; Shan-Chao Zhao; Ming-Kun Chen
Journal:  Aging (Albany NY)       Date:  2021-06-18       Impact factor: 5.682

10.  Favorable mortality-to-incidence ratios of kidney Cancer are associated with advanced health care systems.

Authors:  Wen-Wei Sung; Shao-Chuan Wang; Tzuo-Yi Hsieh; Cheng-Ju Ho; Cheng-Yu Huang; Yu-Lin Kao; Wen-Jung Chen; Sung-Lang Chen
Journal:  BMC Cancer       Date:  2018-08-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.